|
|
|
8 January, 2013
|
| In this Issue |
2012 US Drug Approvals Best in 16 Years. Will the Good Times Last?
Coming out of the blizzard of patent expirations, 2012’s total drug approvals climbed to 39, the greatest number from the FDA since 1996. The evidence is now clear that pipeline preparations laid not just within the year but within the past decade are finally yielding results ... Read more |
The African Markets Pharma Can’t Ignore
In its new study on pharma market growth in Africa, IMS Health highlights three ‘rising stars’ from the continent’s sub-Saharan region that are set to join the more established markets of South Africa, Algeria, Egypt, and Morocco as major countries to watch in the next five to 10 years ... Read more |
Falsified Medicines Directive Takes Shape in Europe
The EU fine-tunes legislation for the Falsified Medicines Directive, which is due to take effect this month as part of efforts to better protect patients from counterfeits ... Read more |
EMA Announces 2013 Plans
The European Medicines Agency promises to increase operational efficiency, enhance transparency and communication with stakeholders, and improve the quality and consistency of rulemaking in 2013 ... Read more
|
Guide to Strategic Outsourcing
Inside Outsourcing, our new eBook featuring the latest articles, analyses and opinion on optimizing CRO/CMO relationships, is available for free download now ... Read more
|
|
| Event Profiles |
 BIO-Europe Spring® 2013 — 7th International Partnering Conference
The seventh annual BIO-Europe Spring® conference is the premier springtime partnering conference for the biotechnology industry. For its 2013 edition, BIO-Europe Spring comes to Barcelona, Spain on March 11–13, 2013.  Read more
|
|
|
|
which country will be the most important emerging market in 2013?
